Results 171 to 180 of about 14,567 (295)
The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn's Disease. [PDF]
Monfort-Ferré D +13 more
europepmc +1 more source
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci +5 more
wiley +1 more source
ABSTRACT Aims To examine the independent and joint associations of metabolic status, obesity, and physical activity with all‐cause and cardiovascular disease (CVD) mortality across metabolic–obesity phenotypes. Materials and Methods We analysed 442 666 adults from the Korean National Health Insurance Service health screening cohort (2009–2012 ...
Yunmin Han +3 more
wiley +1 more source
High-intensity intermittent training promotes adipose tissue browning via the IL-27/p38 MAPK-PGC-1α signaling pathway in diet-induced obese rats. [PDF]
Wang C, Hu Y, Chen J, Wu Y.
europepmc +1 more source
PTPN2 targets TAK1 for dephosphorylation to improve cellular senescence and promote adipose tissue browning in T2DM. [PDF]
Liu Y +8 more
europepmc +1 more source
Reactivation of brown adipose tissue [PDF]
openaire +2 more sources
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano +4 more
wiley +1 more source
Nano-Encapsulated Berberine Is a Potential Therapeutic Agent for Adipose Tissue Browning in C57BL/6J Mice. [PDF]
Alpaslan A +8 more
europepmc +1 more source
Hepcidin deficiency in mice impairs white adipose tissue browning possibly due to a defect in de novo adipogenesis. [PDF]
Deschemin JC +6 more
europepmc +1 more source
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo +18 more
wiley +1 more source

